95 related articles for article (PubMed ID: 30109712)
1. Preparation of a radiolabeled GnRH-I analogue derivative with
Zoghi M; Nosrati SA; Rogni F; Rajabifar S
J Labelled Comp Radiopharm; 2018 Oct; 61(12):903-911. PubMed ID: 30109712
[TBL] [Abstract][Full Text] [Related]
2. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
[TBL] [Abstract][Full Text] [Related]
4. Development of a (68)Ga-peptide tracer for PET GnRH1-imaging.
Zoghi M; Jalilian AR; Niazi A; Johari-Daha F; Alirezapour B; Ramezanpour S
Ann Nucl Med; 2016 Jul; 30(6):400-8. PubMed ID: 27083468
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of novel
Xu J; Feng C; Miao Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4647-4651. PubMed ID: 28917649
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of a new gonadotropin releasing hormone analogue.
Saleh-Abady MM; Naderi-Manesh H; Alizadeh A; Shamsipour F; Balalaie S; Arabanian A
Biopolymers; 2010; 94(3):292-7. PubMed ID: 19908246
[TBL] [Abstract][Full Text] [Related]
8. Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.
Guo H; Hathaway H; Royce ME; Prossnitz ER; Miao Y
Bioorg Med Chem Lett; 2013 Oct; 23(20):5484-7. PubMed ID: 24018188
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
10. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
[TBL] [Abstract][Full Text] [Related]
11. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
13. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
[TBL] [Abstract][Full Text] [Related]
14. Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.
Goodwin D; Varamini P; Simerska P; Toth I
Pharm Res; 2015 May; 32(5):1570-84. PubMed ID: 25407542
[TBL] [Abstract][Full Text] [Related]
15. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
[TBL] [Abstract][Full Text] [Related]
16. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
17. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
18. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
19. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
20. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]